Cargando…

Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer

We present a pilot quality assurance (QA) study of a clinical-scale, automated, third-generation (GEN-3) (129)Xe hyperpolarizer employing batch-mode spin-exchange optical pumping (SEOP) with high-Xe densities (50% natural abundance Xe and 50% N(2) in ~2.6 atm total pressure sourced from Nova Gas Tec...

Descripción completa

Detalles Bibliográficos
Autores principales: Birchall, Jonathan R., Chowdhury, Md Raduanul H., Nikolaou, Panayiotis, Chekmenev, Yuri A., Shcherbakov, Anton, Barlow, Michael J., Goodson, Boyd M., Chekmenev, Eduard Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879294/
https://www.ncbi.nlm.nih.gov/pubmed/35209116
http://dx.doi.org/10.3390/molecules27041327
_version_ 1784658864534192128
author Birchall, Jonathan R.
Chowdhury, Md Raduanul H.
Nikolaou, Panayiotis
Chekmenev, Yuri A.
Shcherbakov, Anton
Barlow, Michael J.
Goodson, Boyd M.
Chekmenev, Eduard Y.
author_facet Birchall, Jonathan R.
Chowdhury, Md Raduanul H.
Nikolaou, Panayiotis
Chekmenev, Yuri A.
Shcherbakov, Anton
Barlow, Michael J.
Goodson, Boyd M.
Chekmenev, Eduard Y.
author_sort Birchall, Jonathan R.
collection PubMed
description We present a pilot quality assurance (QA) study of a clinical-scale, automated, third-generation (GEN-3) (129)Xe hyperpolarizer employing batch-mode spin-exchange optical pumping (SEOP) with high-Xe densities (50% natural abundance Xe and 50% N(2) in ~2.6 atm total pressure sourced from Nova Gas Technologies) and rapid temperature ramping enabled by an aluminum heating jacket surrounding the 0.5 L SEOP cell. (129)Xe hyperpolarization was performed over the course of 700 gas loading cycles of the SEOP cell, simulating long-term hyperpolarized contrast agent production in a clinical lung imaging setting. High levels of (129)Xe polarization (avg. %P(Xe) = 51.0% with standard deviation σ(P)(Xe) = 3.0%) were recorded with fast (129)Xe polarization build-up time constants (avg. T(b) = 25.1 min with standard deviation σ(T)(b) = 3.1 min) across the first 500 SEOP cell refills, using moderate temperatures of 75 °C. These results demonstrate a more than 2-fold increase in build-up rate relative to previously demonstrated results in a comparable QA study on a second-generation (GEN-2) (129)Xe hyperpolarizer device, with only a minor reduction in maximum achievable %P(Xe) and with greater consistency over a larger number of SEOP cell refill processes at a similar polarization lifetime duration (avg. T(1) = 82.4 min, standard deviation σ(T)(1) = 10.8 min). Additionally, the effects of varying SEOP jacket temperatures, distribution of Rb metal, and preparation and operation of the fluid path are quantified in the context of device installation, performance optimization and maintenance to consistently produce high (129)Xe polarization values, build-up rates (T(b) as low as 6 min) and lifetimes over the course of a typical high-throughput (129)Xe polarization SEOP cell life cycle. The results presented further demonstrate the significant potential for hyperpolarized (129)Xe contrast agent in imaging and bio-sensing applications on a clinical scale.
format Online
Article
Text
id pubmed-8879294
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88792942022-02-26 Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer Birchall, Jonathan R. Chowdhury, Md Raduanul H. Nikolaou, Panayiotis Chekmenev, Yuri A. Shcherbakov, Anton Barlow, Michael J. Goodson, Boyd M. Chekmenev, Eduard Y. Molecules Article We present a pilot quality assurance (QA) study of a clinical-scale, automated, third-generation (GEN-3) (129)Xe hyperpolarizer employing batch-mode spin-exchange optical pumping (SEOP) with high-Xe densities (50% natural abundance Xe and 50% N(2) in ~2.6 atm total pressure sourced from Nova Gas Technologies) and rapid temperature ramping enabled by an aluminum heating jacket surrounding the 0.5 L SEOP cell. (129)Xe hyperpolarization was performed over the course of 700 gas loading cycles of the SEOP cell, simulating long-term hyperpolarized contrast agent production in a clinical lung imaging setting. High levels of (129)Xe polarization (avg. %P(Xe) = 51.0% with standard deviation σ(P)(Xe) = 3.0%) were recorded with fast (129)Xe polarization build-up time constants (avg. T(b) = 25.1 min with standard deviation σ(T)(b) = 3.1 min) across the first 500 SEOP cell refills, using moderate temperatures of 75 °C. These results demonstrate a more than 2-fold increase in build-up rate relative to previously demonstrated results in a comparable QA study on a second-generation (GEN-2) (129)Xe hyperpolarizer device, with only a minor reduction in maximum achievable %P(Xe) and with greater consistency over a larger number of SEOP cell refill processes at a similar polarization lifetime duration (avg. T(1) = 82.4 min, standard deviation σ(T)(1) = 10.8 min). Additionally, the effects of varying SEOP jacket temperatures, distribution of Rb metal, and preparation and operation of the fluid path are quantified in the context of device installation, performance optimization and maintenance to consistently produce high (129)Xe polarization values, build-up rates (T(b) as low as 6 min) and lifetimes over the course of a typical high-throughput (129)Xe polarization SEOP cell life cycle. The results presented further demonstrate the significant potential for hyperpolarized (129)Xe contrast agent in imaging and bio-sensing applications on a clinical scale. MDPI 2022-02-16 /pmc/articles/PMC8879294/ /pubmed/35209116 http://dx.doi.org/10.3390/molecules27041327 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Birchall, Jonathan R.
Chowdhury, Md Raduanul H.
Nikolaou, Panayiotis
Chekmenev, Yuri A.
Shcherbakov, Anton
Barlow, Michael J.
Goodson, Boyd M.
Chekmenev, Eduard Y.
Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer
title Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer
title_full Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer
title_fullStr Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer
title_full_unstemmed Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer
title_short Pilot Quality-Assurance Study of a Third-Generation Batch-Mode Clinical-Scale Automated Xenon-129 Hyperpolarizer
title_sort pilot quality-assurance study of a third-generation batch-mode clinical-scale automated xenon-129 hyperpolarizer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879294/
https://www.ncbi.nlm.nih.gov/pubmed/35209116
http://dx.doi.org/10.3390/molecules27041327
work_keys_str_mv AT birchalljonathanr pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer
AT chowdhurymdraduanulh pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer
AT nikolaoupanayiotis pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer
AT chekmenevyuria pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer
AT shcherbakovanton pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer
AT barlowmichaelj pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer
AT goodsonboydm pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer
AT chekmeneveduardy pilotqualityassurancestudyofathirdgenerationbatchmodeclinicalscaleautomatedxenon129hyperpolarizer